We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Read MoreHide Full Article
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) announced positive top-line data from a pivotal phase III study on recombinant human beta-glucuronidase (rhGUS) for the treatment of mucopolysaccharidosis 7 (MPS 7), also known as Sly syndrome.
The study assessed the safety and efficacy of rhGUS in patients (n=12) aged 5–35 years.
Data demonstrated a rapid and sustained reduction of 64.8% from baseline in urinary GAG (dermatan sulfate) excretion after 24 weeks of treatment, thereby meeting the primary endpoint. It also provided evidence of clinical improvement. Treatment-emergent adverse events were generally mild to moderate in severity. Results from the study are being presented at the International Symposium on MPS and Related Diseases.
Ultragenyx intends to meet regulatory authorities in both the U.S. and the EU to discuss plans to submit regulatory filings in the first half of 2017.
We note that MPS 7 represents an underserved market with no approved therapies presently available. A potential approval and successful commercialization of rhGUS will thus be a major boost for the company.
Drugs currently approved for the treatment of other MPS disorders include Aldurazyme, Elaprase, Vimizim and Naglazyme.
Meanwhile, Ultragenyx continues to progress on its pipeline. Currently, the company is evaluating aceneuramic acid extended release (Ace-ER) in a pivotal phase III study for the treatment of patients with GNE myopathy. Results are expected in 2017.
Moreover, the company has filled a marketing application for Ace-ER in the EU, based on phase II results for the treatment of adult patients with GNE myopathy. A response from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for Human Use (CHMP) is expected in the second half of 2016.
We expect investor focus to remain on further pipeline updates from the company.
Currently, Ultragenyx carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Merrimack Pharmaceuticals, Inc. (MACK - Free Report) , Pfizer Inc. (PFE - Free Report) and Innoviva, Inc. (INVA - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Ultragenyx Pharmaceutical Inc. (RARE - Free Report) announced positive top-line data from a pivotal phase III study on recombinant human beta-glucuronidase (rhGUS) for the treatment of mucopolysaccharidosis 7 (MPS 7), also known as Sly syndrome.
The study assessed the safety and efficacy of rhGUS in patients (n=12) aged 5–35 years.
Data demonstrated a rapid and sustained reduction of 64.8% from baseline in urinary GAG (dermatan sulfate) excretion after 24 weeks of treatment, thereby meeting the primary endpoint. It also provided evidence of clinical improvement. Treatment-emergent adverse events were generally mild to moderate in severity. Results from the study are being presented at the International Symposium on MPS and Related Diseases.
Ultragenyx intends to meet regulatory authorities in both the U.S. and the EU to discuss plans to submit regulatory filings in the first half of 2017.
ULTRAGENYX PHAR Price
ULTRAGENYX PHAR Price | ULTRAGENYX PHAR Quote
We note that MPS 7 represents an underserved market with no approved therapies presently available. A potential approval and successful commercialization of rhGUS will thus be a major boost for the company.
Drugs currently approved for the treatment of other MPS disorders include Aldurazyme, Elaprase, Vimizim and Naglazyme.
Meanwhile, Ultragenyx continues to progress on its pipeline. Currently, the company is evaluating aceneuramic acid extended release (Ace-ER) in a pivotal phase III study for the treatment of patients with GNE myopathy. Results are expected in 2017.
Moreover, the company has filled a marketing application for Ace-ER in the EU, based on phase II results for the treatment of adult patients with GNE myopathy. A response from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for Human Use (CHMP) is expected in the second half of 2016.
We expect investor focus to remain on further pipeline updates from the company.
Currently, Ultragenyx carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Merrimack Pharmaceuticals, Inc. (MACK - Free Report) , Pfizer Inc. (PFE - Free Report) and Innoviva, Inc. (INVA - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>